Bleomycin‑based electrochemotherapy for the treatment of a Buschke‑Löwenstein tumor (perianal giant condyloma) in an HIV‑positive kidney transplant recipient: A case report
- Authors:
- Published online on: November 7, 2022 https://doi.org/10.3892/ol.2022.13586
- Article Number: 466
-
Copyright: © Russano et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
The Buschke‑Löwenstein tumor (BLT), also known as giant condyloma acuminatum, is a rare sexually transmitted disease often associated with human papillomavirus types 6 and 11. There are no specific guidelines for treating BLT. Surgery is the preferred treatment, although it can have profound consequences on a patient's quality of life. A 41‑year old male, who was HIV‑positive and a kidney transplant recipient treated with cyclosporine, was referred to the Veneto Institute of Oncology (Soft‑Tissue, Peritoneum and Melanoma Surgical Oncology Unit) after a two‑year history of perianal warts that always relapsed after surgical treatment. A multidisciplinary evaluation was conducted to assess an individually tailored treatment plan. Tailored bleomycin‑based electrochemotherapy (ECT) was proposed in order to achieve local disease control and preserve kidney function. A total of three cycles of ECT with a 25%‑reduced dose of intravenous bleomycin (11,250 IU/m2) were administered, and a complete response was achieved 20 months after the final ECT session.
